Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 8.01
This Item 8.01 discloses a material acquisition event: Catalyst Pharmaceuticals entered into a Merger Agreement with Angelini Pharma on May 6, 2026, providing for the merger of Angelini's subsidiary with Catalyst, with Catalyst surviving as a wholly-owned subsidiary of Angelini Pharma. The filing updates that the FTC granted early termination of the HSR Act waiting period on June 16, 2026, and the parties expect closing in Q3 2026 subject to customary conditions including stockholder approval. This is a change-of-control transaction material to any reasonable investor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
FibroBiologics held its Annual Meeting on June 22, 2026, with stockholders voting on four proposals: election of Class III director Pete O'Heeron, ratification of WithumSmith+Brown, PC as independent auditor, approval of warrant issuance under Nasdaq Rule 5635(d), and approval of the 2026 Equity and Incentive Compensation Plan. All proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-23
Item 5.02
Stockholders approved and adopted the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan, which authorizes 2,061,968 shares and enables the Compensation Committee to grant equity-based and cash-based compensation to employees, officers, consultants, and directors, including performance-based awards and evergreen provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-23
Item 5.02
The filing discloses the appointment of Robert Azelby as a director of Tango Therapeutics, effective June 19, 2026, to fill a newly created board vacancy. While the disclosure also includes compensatory arrangements (equity awards and retainers), the principal action is the appointment itself. The appointment of an experienced biopharmaceutical executive with 30+ years of industry leadership to the board of a clinical-stage biotech company is material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of United Parks & Resorts' 2026 Annual Meeting of Stockholders held on June 16, 2026. The filing presents detailed voting tallies for four proposals: election of ten directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on say-on-pay frequency. All proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-23
Item 8.01
Enanta disclosed an adverse Federal Circuit court ruling affirming summary judgment that invalidated claims of U.S. Patent No. 11,358,953 in its patent infringement suit against Pfizer over Paxlovid. This is a material litigation outcome involving a major pharmaceutical competitor and a core patent asset, directly affecting the Company's ability to recover damages and enforce its intellectual property rights.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-06-23
Item 8.01
Republic Services agreed to issue $700 million of 4.750% notes due 2031 and $500 million of 5.000% notes due 2036 pursuant to an Underwriting Agreement dated June 22, 2026, creating $1.2 billion in material direct financial obligations.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-23
EX-99.1
Equinox Gold Corp. proposed to acquire all outstanding common shares of Orla Mining Ltd. by way of a court-approved plan of arrangement, with an exchange ratio of 1.00 Equinox Gold share plus $0.0001 cash per Orla share, involving the issuance of up to 421.8 million Equinox Gold shares. The transaction, described as transformative, requires shareholder approval at a special meeting scheduled for July 22, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-23
Item 2.02
EagleRock issued a press release on June 23, 2026 disclosing preliminary pro forma financial results for the quarter ended March 31, 2026, including revenue ($29.6–$36.1 million), net income ($13.3–$16.2 million), and Adjusted EBITDA ($25.7–$31.5 million). The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. Although the results are preliminary and unaudited pro forma figures (due to the company's recent IPO on May 15, 2026), this constitutes a material disclosure of quarterly financial results to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-23
Item 1.01
This disclosure reports Amendment No. 1 to a business combination agreement (BCA) between Eureka Acquisition Corp (SPAC), Marine Thinking Inc., and an amalgamation subsidiary, dated June 12, 2026. The amendment modifies post-closing director requirements under section 5.19 of the original BCA filed October 29, 2025. Material amendments to definitive M&A agreements constitute ma_activity under Item 1.01, as they affect the terms and conditions of the pending business combination.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-06-23
EX-99.1
This investor presentation discloses CLPS Inc's full fiscal year 2025 financial results (revenue $164.5M, net loss $(6.4)M) and H1 FY2026 interim results (revenue $85.1M, net income $0.3M), marking a return to profitability. The presentation includes detailed revenue breakdowns by service line, geography, and operational area, along with forward guidance of 10–15% revenue growth for FY2026. While formatted as a presentation rather than a traditional press release, it functions as a comprehensive earnings disclosure of material financial results and is clearly intended for investor communication.
View raw filing on EDGAR →
6-K
Other material
confidence 75%
filed 2026-06-23
EX-99.1
The press release announces a plan to implement a 1-for-25 reverse ADS split (changing the ADS ratio from 1 ADS per 18 ordinary shares to 1 ADS per 450 ordinary shares), effective June 25, 2026. While this is a capital structure event affecting the trading mechanics of the company's ADSs on NASDAQ, it does not fit neatly into the standard taxonomy categories. It is not a dilutive issuance (no new securities issued), not a dividend distribution, and not a governance matter in the traditional sense. The event is material to investors as it affects the trading price and share structure, but the specific mechanism—a reverse ADS split—does not align with any named event type, warranting classification as `other_material`.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-23
The filing discloses Item 5.02 approval by the Compensation Committee of one-time special discretionary cash bonus awards to the CEO ($250,000) and CFO ($100,000), explicitly recognizing their contributions to the Company's NYSE American listing, strategic repositioning toward AI/HPC infrastructure, and data center pipeline development. This is a compensatory arrangement for named executives, distinct from a departure or appointment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This press release announces a strategic partnership between Park Ha Biological and Cloud Factory Technology Holdings to develop an AI-driven ecosystem for the beauty industry. The disclosure describes a comprehensive collaboration involving technology integration, operational efficiency improvements, and supply chain optimization. While not a traditional M&A transaction, this strategic partnership represents a material operational and business development event that would affect a reasonable investor's assessment of the company's growth strategy and competitive positioning. The partnership is characterized as "a pivotal milestone" in the company's transition to "data-driven, intelligent, and lean operational growth."
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-23
The 6-K discloses results of an extraordinary general meeting of shareholders held on June 18, 2026, with voting tallies for four distinct proposals: (1) approval of a massive increase in authorized share capital from US$20 million to US$10 billion, (2) adoption of amended memorandum of association reflecting the capital increase, (3) approval of share consolidation at a ratio between 2:1 and 250:1 at board discretion, and (4) adoption of amended memorandum and articles reflecting the consolidation. All four proposals passed with substantial majorities. These are material structural changes to the company's capitalization and governance requiring shareholder approval.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This press release announces a strategic partnership agreement between Youlife Group Inc. and Anhui Thingo Intelligent Technology Co., Ltd to develop AI-powered workforce solutions across three domains: AI agent business development, AI-powered recruitment systems, and vocational education partnerships. The partnership represents a material operational and strategic initiative that would affect a reasonable investor's assessment of the company's business direction and growth opportunities, particularly as management commentary emphasizes it enables evolution from a labor-intensive services provider into a human-AI collaboration platform with "substantial new revenue opportunities going forward."
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-23
Item 1.01
HeartSciences entered into a definitive Agreement and Plan of Merger with Fortitude Mining Holdings, Inc. on June 23, 2026, whereby Fortitude will merge with HeartSciences' subsidiary in an all-stock transaction expected to close in H2 2026. The transaction represents a material change of control, with Fortitude's parent DCG expected to own approximately 95% of the combined company post-closing and HeartSciences shareholders retaining approximately 5%, fundamentally transforming HeartSciences' business and ownership structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 2.01
Quantum Computing Inc. completed the acquisition of NHanced Semiconductors, Inc. for $73.1 million in upfront consideration (cash and stock) plus up to $72.0 million in earnout payments. The acquisition adds semiconductor and nanophotonics fabrication capabilities and launches Fab 2 to accelerate the company's path to commercial-scale production.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
Faraday Future announced the launch of new robotics products (the All-New Futurist humanoid robot and FF Faber mobile manipulator series) and previewed its industrial ecosystem strategy at the Automate conference in Chicago. The disclosure emphasizes product innovation, pricing ($89,900 for the Futurist), expected June shipments exceeding 100 units, and strategic expansion into industrial applications. This is a material operational and strategic business event—a significant product launch and market expansion milestone—but does not fit the specific categories of M&A, earnings release, or other named event types. The company is disclosing material progress on its core business strategy and product roadmap.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-23
EX-99.1
This press release announces receipt of follow-on orders from an existing governmental customer for Maris-Tech's edge video and AI systems. While the disclosure does not specify order value or financial impact, the announcement emphasizes repeat orders from an intelligence customer already operating the company's systems in mission-critical environments, signaling sustained customer confidence and ongoing operational deployment. This is a material business development—a significant customer contract or order—that does not fit the specific categories of earnings release, M&A activity, or other named event types, making it an operational business event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-23
EX-99.1
This is a corporate presentation disclosing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305, with planned IND submission in 2027 and Phase 1 initiation in H1 2027. The presentation details the company's technology, mechanism of action, and development roadmap for immuno-oncology candidates. While this is a strategic/operational disclosure of product development milestones and platform capabilities rather than a discrete event like M&A or earnings, it represents material progress on the company's core pipeline and would affect a reasonable investor's assessment of the registrant's development trajectory and value creation potential.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
Shareholders voted at the June 16, 2026 annual meeting on three proposals: setting board size at six directors, electing six director nominees (Michael McFadden, Kenneth Cawkell, Rajeev Bakshi, Phillip Mertz, Robert Wills, and Bethany Sensenig), and ratifying CBIZ CPAs P.C. as the independent auditor. All three proposals passed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-23
Item 5.02
The Board appointed Dr. Robert Wills as non-executive Chair of the Board following the June 16, 2026 annual meeting, a material change to the registrant's senior leadership structure.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-06-23
EX-99.1
This press release discloses first-instance court rulings in patent litigation between Xiao-I's subsidiary Shanghai Xiao-I and Apple Inc. regarding alleged infringement of a chat robot patent by Apple's Siri technology. The Shanghai High People's Court dismissed Xiao-I's infringement claims and ruled that iPhone models with Siri do not infringe the patent. The Company intends to appeal to the Supreme People's Court. This is a material litigation development affecting the Company's intellectual property rights and potential financial recovery.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-23
Item 5.07
This Item 5.07 discloses the results of a Special Meeting of Stockholders held on June 23, 2026, where shareholders voted on multiple material matters: election of a Class I director (Lauren Chung), approval of a reverse stock split amendment (1-for-5 to 1-for-200 ratio), approval of convertible preferred stock issuance to Bio Insights LLC for asset acquisition, approval of potential dilutive issuance upon conversion of a promissory note to NorthView Sponsor I LLC, and amendment to the 2025 Equity and Incentive Plan. The filing presents detailed vote tallies for each proposal, which is the core disclosure required by Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-23
Item 7.01
The filing discloses the election of Li Shanglong (Michael Li) as new Chairman and the appointment of Shao Weizhi (Eric Shao) as new Chief Executive Officer, following the resignation of James Li from both CEO and Chairman roles. While the filing involves both a departure and appointments, the principal disclosed action centers on the appointment of two new senior executives to lead the company's strategic transformation. The detailed biographical information and Board's rationale for the appointments underscore their materiality to investors assessing leadership continuity and strategic direction.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-23
Item 8.01
SCWorx received a Nasdaq Hearings Panel decision on June 17, 2026 granting continued listing subject to strict compliance conditions: obtaining shareholder approval for a reverse stock split by July 22, 2026, effecting the split by August 3, 2026, and demonstrating a $1.00+ closing bid price for 20 consecutive trading days by August 28, 2026. Failure to meet these deadlines will result in delisting from Nasdaq. This is a material delisting-risk disclosure under Item 3.01 framework, as the company faces imminent delisting if conditions are not satisfied.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-06-23
The 6-K discloses the appointment of Kun Yang as an independent director and member of three board committees, including chair of the Corporate Governance and Nominating Committee, effective June 18, 2026. While the filing also mentions the concurrent resignation of Bin Wu, the principal disclosed action is the appointment of a new director to fill the vacancy. The appointment includes detailed biographical information and confirmation of independence under Nasdaq rules, indicating material governance significance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This press release announces the first successful clinical treatment of a glioblastoma patient outside the United States using Alpha Tau's proprietary Alpha DaRT technology, performed at Hadassah University Medical Center in Israel. The disclosure represents a material operational and clinical milestone for the company's development program—the first international application of the brain-specific delivery system and a proof-of-concept for the technology in a high-unmet-need indication. While not a discrete event type (not M&A, not an earnings release, not an executive change), this clinical achievement is material to investors assessing the company's progress toward commercialization and regulatory approval of its core therapeutic platform.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
INmune Bio announced receipt of official MHRA written alignment from a pre-MAA Scientific Advice meeting for CORDStrom™ (Ebstrocel™) in RDEB, confirming agreement on CMC, non-clinical, and clinical evidence packages and providing a "clear regulatory path" for a planned 2026 UK Marketing Authorization Application. This is a material regulatory milestone de-risking the development program and advancing the company toward a key commercialization objective, but it is not a completed M&A transaction, earnings release, executive change, or other specifically-named event type—it is a significant operational/regulatory milestone in the drug development lifecycle.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 1.01
Zoomcar entered into a securities purchase agreement for a private placement of Series A Convertible Preferred Stock, Warrants, and Placement Agent Warrants under Section 4(a)(2) and Regulation D Rule 506(c), with the Second Closing involving issuance of 662 Units for approximately $537,000 in gross proceeds. The Preferred Shares are convertible into Common Stock at $0.05 per share and Warrants are exercisable at $0.0625 per share, materially diluting existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
Alto Ingredients held its 2026 Annual Meeting of Stockholders on June 23, 2026, with voting results on four proposals: election of five directors (Gilbert E. Nathan, Bryon T. McGregor, Dianne S. Nury, Maria G. Gray, and Alan R. Tank), say-on-pay approval of 2025 named executive officer compensation, approval of the 2026 Omnibus Incentive Plan, and ratification of RSM US LLP as independent auditor.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-23
Item 1.01
Aditxt entered into Amendment No. 1 to a Note Purchase Agreement on June 22, 2026, increasing the aggregate principal amount of senior secured convertible notes to $6,254,355.17 and issuing an additional $769,230.77 in principal amount for $500,000 in cash.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-23
Item 3.02
Aditxt conducted an unregistered sale of equity securities (Additional Notes) to accredited investors under Section 4(a)(2) and Regulation D Rule 506(b), representing a material private placement exempt offering.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-23
Item 8.01
CBAK Energy completed a redomicile merger on June 23, 2026, reorganizing from a Nevada corporation to a Cayman Islands exempted company. While this is a merger transaction, it is a change-of-control reorganization driven by governance and tax/administrative considerations rather than a traditional M&A activity. The filing emphasizes that "the Redomicile Merger did not change the Company's business, day-to-day operations, strategy, operating subsidiaries, management team, employees, production facilities, customer and supplier relationships, or consolidated assets and liabilities," and the stated purpose was to "reduce certain ongoing operational, administrative, legal and accounting costs, simplify corporate administration." This is fundamentally a governance restructuring with material implications for shareholders (change in domicile, corporate structure, and future flexibility), making it material but best classified as a governance event rather than traditional M&A.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-23
E-Power Inc. entered into a subscription agreement on June 16, 2026, to issue 15,841,585 Class A ordinary shares at $1.01 per share for an aggregate purchase price of $16,000,000.85 to a non-U.S. purchaser under Regulation S. This is a private placement of equity securities that will dilute existing shareholders and raise capital, fitting the definition of dilutive_issuance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-23
Item 2.03
The Company issued an unsecured promissory note for $200,000 to Nautilus Energy Management Corp., creating a direct financial obligation. Although the note is convertible into equity units upon business combination consummation, the primary disclosed event is the creation of a debt instrument.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-23
Item 3.02
The Company completed an unregistered private placement of a convertible note that would result in issuance of 20,000 private placement units upon conversion, together with warrants exercisable for Class A ordinary shares, relying on Section 4(a)(2) exemption for sophisticated investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-23
The 6-K discloses a registered direct offering of 6,441,012 Class A ordinary shares at US$0.45645 per share for aggregate gross proceeds of approximately US$2.94 million. This is a direct equity issuance to investors pursuant to a Securities Purchase Agreement dated June 19, 2026, and is expected to close on or about June 25, 2026. The offering is registered under Form F-3 and represents a material capital-raising event that would dilute existing shareholders.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-23
EX-99.1
The exhibit is a press release announcing that Nasdaq has determined to delist Smart Digital Group Limited's securities pursuant to Nasdaq Listing Rule IM-5101-4, following an SEC trading suspension issued on September 29, 2025. The Company has until June 24, 2026 to appeal, and if no appeal is filed, trading will be suspended on June 26, 2026 and Nasdaq will file a Form 25-NSE to complete the delisting. This is a direct delisting determination notice, which is a material event affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-23
The filing discloses conversion of Series B Convertible Preferred Stock into common stock following stockholder approval at a June 12, 2026 special meeting. The conversion resulted in 53,539,119 shares of common stock outstanding as of June 17, 2026, and required Nasdaq Listing Rule 5635(d) approval because the issuance exceeded 19.99% of previously outstanding shares. This is a material dilutive issuance of equity securities that materially increases share count and would affect investor assessment of ownership dilution and voting power.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-23
Item 5.03
Smart Powerr Corp. effected a 1-for-10 reverse stock split on June 17, 2026, primarily to bring the company into compliance with Nasdaq Capital Market's minimum bid price requirement. The company acknowledged material uncertainty regarding its ability to timely regain or maintain compliance with continued listing standards.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 1.01
Silicon Valley Acquisition Corp. (SVAQ) entered into a Business Combination Agreement with EigenQ, Inc. on June 17, 2026, pursuant to which SVAQ's merger subsidiary will merge with EigenQ, with EigenQ continuing as the surviving company and becoming a wholly-owned subsidiary of SVAQ. This is a material acquisition/change of control transaction with a $2.93 billion valuation, requiring shareholder approval and resulting in a combined company listing on a national securities exchange. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement) and describes the merger structure, consideration, and post-closing governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 7.01
HeartSciences entered into a definitive Agreement and Plan of Merger with Fortitude Mining Holdings on June 23, 2026, combining the two companies in an all-stock transaction. The merger agreement is a material acquisition/change of control event, with the combined company expected to operate under the Fortitude brand and trade on Nasdaq. This is disclosed in Item 7.01 (Regulation FD Disclosure) and is supported by the conference call transcript and social media posts furnished as exhibits, which detail the transaction structure, financial profile, and strategic rationale.
View raw filing on EDGAR →
8-K
Restatement
confidence 98%
filed 2026-06-23
Item 4.02
The Board determined on June 23, 2026 that the Company's previously issued financial statements for fiscal years 2022–2025 should no longer be relied upon due to improper recognition of a $499.4 million intangible asset and audit report deficiencies from Olayinka Oyebola & Co. Management has concluded the asset should be removed and the Affected Financial Statements restated, which will materially reduce total assets and stockholders' equity. This is a classic non-reliance and restatement disclosure under Item 4.02.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-23
Item 2.01
The filing discloses the completed sale of the Hilton Garden Inn Austin Downtown hotel property by Ashford Hospitality Trust's subsidiary for $26.85 million in cash on June 18, 2026, pursuant to an Agreement of Purchase and Sale dated April 30, 2026. This is a material disposition of a hotel asset that would affect a reasonable investor's assessment of the company's portfolio and financial position. The supplemental pro forma statements demonstrate the significance of the transaction, showing removal of $23.8 million in net hotel property value and $25.7 million in associated mortgage debt.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-06-23
EX-99.1
This is a definitive announcement of a material acquisition: Ballard Power Systems has entered into a definitive agreement to acquire UK-based GeoPura Limited for total upfront consideration of £275.0 million (~US$400 million enterprise value), funded through £82.5 million in cash and ~50.8 million newly issued Ballard shares. The transaction is transformative, establishing Ballard as a vertically integrated hydrogen ecosystem provider, and includes contingent consideration of up to £27.5 million. The acquisition is expected to close in H2 2026 and has been unanimously approved by both boards.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This news release discloses updated mineral reserves and resources for Silvercorp's Gaocheng Mine as of December 31, 2025, prepared in accordance with NI 43-101. The disclosure reports significant changes in resource estimates (59% increase in Measured and Indicated tonnes, 23-25% increase in contained metals) and reserve estimates (25% increase in tonnes), along with a revised life-of-mine production profile and NPV projection of $101.4M. While not a discrete operational event like a contract or partnership, this technical update materially affects investor assessment of the mine's economic viability and production potential, making it a material operational disclosure that does not fit the specific categories of earnings release, impairment, or workforce reduction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-23
EX-99.1
This news release announces the filing of meeting materials and receipt of an interim court order for Orla Mining's special shareholder meeting to approve a material acquisition—specifically, a court-approved plan of arrangement whereby Equinox Gold Corp. will acquire all outstanding common shares of Orla. The arrangement agreement was dated May 12, 2026, and shareholders will vote on July 22, 2026. The Board unanimously recommends approval, and insiders holding 26.4% of shares have committed to vote in favor. This is a transformative M&A event creating a combined North American senior gold producer.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 75%
filed 2026-06-23
This is a proxy statement and notice for Vale's Extraordinary General Meeting scheduled for July 22, 2026, which will address three items: (1) removal of Daniel André Stieler from the Board of Directors, (2) election of a replacement director, and (3) election of a new Chairman. While the document itself is a notice and proxy solicitation rather than a report of results, it discloses material governance matters—specifically the removal of a board member and election of new leadership—that constitute shareholder voting events. The Board's message emphasizes governance enhancement and board strengthening, indicating these are material governance changes. However, since this is a prospective notice rather than a results disclosure, `shareholder_vote_results` is the closest fit, though the actual vote results are not yet reported.
View raw filing on EDGAR →